Valsartan Drug Recall Notice

Valsartan Drug Recall Information


Valsartan Drug Recall Notice

On July 16, 2018, a voluntary recall of valsartan and valsartan/Hydrochlorothiazide (HCTZ) tablets was issued. This is a generic medication used to treat high blood pressure and heart failure. An impurity, N-nitrosodimethylamine (NDMA) was detected in some generic manufacturer’s products. NDMA is classified as a probable human carcinogen…. Read More



2019 HSA/HDHP Limits

The IRS has announced updated inflation-adjusted HSA contribution limits as well as Out-Of-Pocket Maximum (OOP) expenses for health benefit plans.

In 2019, the HSA contribution limit will have minor increases to $3,500 for a single (an increase of $50) and $7,000 for family (an increase of $100).

The minimum deductible for a high-deductive health plan will have no changes, however, maximum will increase to $6,750 for the single (an increase of $100) and $13,500 for family (an increase of $200).

The maximum OOP limits for non-grandfathered plans will increase to $7,900 for single and $15,800 for the family.

Valsartan Drug Recall table for cost effect

Articles & Announcements

COVID Vaccine Update: Understanding Immunity and Potential for Boosters
FDA Approves Alzheimer’s Drug: Aduhelm
Confidio Expands Investment in Innovation and Continues to Grow Team
Important Changes in Healthcare Promoting Drug Price Transparency
COVID Vaccine Update
Breaking Down Barriers to Cancer Treatment: Problems and Solutions
Is your specialty drug management program only addressing half of your specialty spend?
The High Cost of Hemophilia A Treatments
Navigating HIV PrEP and the Affordable Care Act
Amazon launches “Amazon Pharmacy”, an online pharmacy store
The COVID Vaccine Derby: A Guide to the Top Contenders
Updated executive order on drug pricing, signed by President Trump
Confidio Hires 18 New Employees, Including 3 Strategic Executives
Are Brand-Name Drugs Safer Than Generics?
Understanding COVID-19’s Impact on pharmacy, the Economy and Our Future
President Trump’s Executive Orders on Drug Pricing
CONFIDIO Ranks No. 452 on the 2020 Inc. 5000 With Three-Year Revenue Growth of 1014.66%
Health Alert Updates: COVID-19
Emerging Treatments for Peanut Allergies
HHS Deploys Strategy to Import Drugs From Canada
White House reversal on Proposal to Eliminate Drug Rebates and Pushing Discounts to Point-of-Sale
BBJ’s Employee Benefits Administrators Listing
Will the Rebate Bubble Burst?
Valsartan Drug Recall Notice
Pharmacy Benefits 2020: Ready to Spend Half of Your Medical Plan Budget on Rx?
Pharmacy Predictions: 2019